Welcome, Guest. Please login or register.
April 20, 2024, 06:36:09 pm

Login with username, password and session length


Members
  • Total Members: 6307
  • Latest: golfer
Stats
  • Total Posts: 55126
  • Total Topics: 4851
  • Online Today: 91
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 am)
Users Online
Users: 0
Guests: 29
Total: 29

Welcome

Welcome to the Hep Forums, a round-the-clock discussion area for people who have Fatty Liver Disease, Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Gilead's New Hepatitis C Drug, Sovaldi (Sofosbuvir) approved  (Read 11283 times)

0 Members and 1 Guest are viewing this topic.

Offline iana5252

  • Administrator
  • Member
  • Posts: 187
Gilead's New Hepatitis C Drug, Sovaldi (Sofosbuvir) approved
« on: December 07, 2013, 08:24:51 am »
The U.S. Food and Drug Administration has approved Gilead Sciences’ hotly anticipated Sovaldi (sofosbuvir), a once-daily oral nucleotide analog polymerase inhibitor to treat people with hepatitis C virus (HCV), including those coinfected with HIV and those who have liver cancer and are awaiting a transplant. For those with genotypes 2 and 3 of the virus, Sovaldi offers the first-ever opportunity for treatment with an interferon-free drug regimen. Those with genotypes 1 and 4, however, will in most cases still require the injectable interferon, which causes flu-like side effects.

Sovaldi must be taken in combination with ribavirin regardless of genotype. The recommended treatment duration is 12 weeks for genotypes 1, 2 and 4, and 24 weeks for genotype 3.

Gilead also states that those with genotype 1 who are ineligible to take interferon "can be considered" to receive Sovaldi and ribavirin for 24 weeks of treatment. Also, for those awaiting a liver transplant, the same combination should be given for up to 48 weeks before transplantation to prevent post-transplant infection with the virus.

Read more...
http://www.hepmag.com/articles/Sovaldi_sofosbuvir_2501_24907.shtml

Offline jberlin

  • Global Moderator
  • Member
  • Posts: 319
  • Contracted Hep C in 76, treated 2004 & 2012, cured
Re: Gilead's New Hepatitis C Drug, Sovaldi (Sofosbuvir) approved
« Reply #1 on: December 07, 2013, 03:47:43 pm »
The best news of all is the reduction of treatment times!  12 weeks of interferon for geno 1 is much better than 24 or 48 weeks! And no interferon for Geno 2.  It seems the side effects are much more tolerable than the Incivek treatment. I wonder if the cure rates will measure up, I hope so.  This is great news, and it looks like there is even more coming in 2014. -jack

 


© 2024 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.